For instance, genomicstudies have identified risk-stratifying immune-related loci in relation to AD, suchas TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) and CD33 (Cluster ofDifferentiation 33), (23,24), while TMEM106B (Triggering Receptor Expressed onMyeloid Cells 106B) and LRRK2 (Leucine-Rich Repeat Kinase 2) have been detected asimmune-related variants affecting pathology in frontotemporal dementia (FTD) (25,26)and Parkinson’s disease (27,28), respectively. This evidence concerns the gene LRRK2 and Alzheimer disease.